162 related articles for article (PubMed ID: 35451707)
1.
Gao J; Meng L; Xu Q; Zhao X; Deng Y; Fu Y; Guo S; He K; Shi J; Wang F; Zhang S; Guo H
Mol Imaging Biol; 2022 Oct; 24(5):759-768. PubMed ID: 35451707
[TBL] [Abstract][Full Text] [Related]
2. [
Meng L; Zhang S; Gao J; Xu Q; Fu Y; Zhou YH; Wang F; Guo H
Eur Radiol; 2022 Sep; 32(9):6545-6553. PubMed ID: 35357538
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive evaluation of
Gao J; Xu Q; Fu Y; He K; Zhang C; Zhang Q; Shi J; Zhao X; Wang F; Guo H
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):561-569. PubMed ID: 32623502
[TBL] [Abstract][Full Text] [Related]
4. [
Lin R; Wang C; Chen S; Lin T; Cai H; Chen S; Yang Y; Zhang J; Xu F; Zhang J; Chen X; Zang J; Miao W
Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):535-547. PubMed ID: 37728667
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. Potential role of
Aggarwal P; Singh H; Das CK; Mavuduru RS; Kakkar N; Lal A; Gorsi U; Kumar R; Mittal BR
Eur J Radiol; 2024 Jan; 170():111218. PubMed ID: 38007857
[TBL] [Abstract][Full Text] [Related]
7. Head-to-head comparisons of enhanced CT, 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in identifying adverse pathology of clear-cell renal cell carcinoma: a prospective study.
Chen SH; Lin BH; Chen SM; Qiu QR; Ruan ZT; Chen ZJ; Wei Y; Zheng QS; Xue XY; Miao WB; Xu N
Int Braz J Urol; 2023; 49(6):716-731. PubMed ID: 37624658
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic potential of PET/CT using a
Sawicki LM; Buchbender C; Boos J; Giessing M; Ermert J; Antke C; Antoch G; Hautzel H
Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):102-107. PubMed ID: 26996777
[TBL] [Abstract][Full Text] [Related]
9. Exploration of
Wang B; Deng Y; Xu Q; Gao J; Shen H; He X; Ding Q; Wang F; Guo H
Clin Radiol; 2023 May; 78(5):e417-e424. PubMed ID: 36805287
[TBL] [Abstract][Full Text] [Related]
10. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
Franklin A; Yaxley WJ; Raveenthiran S; Coughlin G; Gianduzzo T; Kua B; McEwan L; Wong D; Delahunt B; Egevad L; Samaratunga H; Brown N; Parkinson R; Roberts MJ; Yaxley JW
BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
[TBL] [Abstract][Full Text] [Related]
11. Special issue "The advance of solid tumor research in China": 68Ga-PSMA-11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma.
Li Y; Zheng R; Zhang Y; Huang C; Tian L; Liu R; Liu Y; Zhang Z; Han H; Zhou F; He L; Dong P
Int J Cancer; 2023 Jan; 152(1):42-50. PubMed ID: 35751420
[TBL] [Abstract][Full Text] [Related]
12. Diverse PSMA expression in primary prostate cancer: reason for negative [
Cytawa W; Kircher S; Kübler H; Werner RA; Weber S; Hartrampf P; Bandurski T; Lass P; Połom W; Matuszewski M; Wester HJ; Lapa C; Rosenwald A; Seitz AK; Buck AK
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3938-3949. PubMed ID: 35556160
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical Validation of PSMA Expression Measured by
Woythal N; Arsenic R; Kempkensteffen C; Miller K; Janssen JC; Huang K; Makowski MR; Brenner W; Prasad V
J Nucl Med; 2018 Feb; 59(2):238-243. PubMed ID: 28775203
[No Abstract] [Full Text] [Related]
14. Correlation of Lesional Uptake Parameters and Ratios with miPSMA Score and Estimating Normal Physiologic Concentration: An Exploratory Analysis in Metastatic Castration-Resistant Prostatic Carcinoma Patients with
Kalshetty A; Menon B; Rakshit S; Bhattacharjee A; Basu S
J Nucl Med Technol; 2021 Sep; 49(3):235-240. PubMed ID: 34244223
[TBL] [Abstract][Full Text] [Related]
15.
Mittlmeier LM; Todica A; Gildehaus FJ; Unterrainer M; Beyer L; Brendel M; Albert NL; Ledderose ST; Vettermann FJ; Schott M; Rodler S; Marcon J; Ilhan H; Cyran CC; Stief CG; Staehler M; Bartenstein P
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1711-1720. PubMed ID: 34708249
[TBL] [Abstract][Full Text] [Related]
16. Establishment and prospective validation of an SUV
Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
[No Abstract] [Full Text] [Related]
17. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
18. Comparison of [
Uprimny C; Svirydenka A; Fritz J; Kroiss AS; Nilica B; Decristoforo C; Haubner R; von Guggenberg E; Buxbaum S; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2018 Oct; 45(11):1873-1883. PubMed ID: 29766246
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Value of
Wang B; Gao J; Zhang Q; Fu Y; Liu G; Shi J; Li D; Wang F; Guo H
J Nucl Med; 2020 Jun; 61(6):873-880. PubMed ID: 31757845
[TBL] [Abstract][Full Text] [Related]
20. How accurate is
Erdem S; Simsek DH; Degirmenci E; Aydin R; Bagbudar S; Ozluk Y; Sanli Y; Sanli O; Ozcan F
Urol Oncol; 2022 Jan; 40(1):6.e1-6.e9. PubMed ID: 34400066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
